参考文献[1]
TaillibertS, Le RhunÉ. [Epidemiology of brain metastases][J]. Cancer Radiother, 2015，19(1): 3-9. .
[2]
SperdutoPW, KasedN, RobergeD, et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases[J]. J Clin Oncol, 2012，30(4): 419-425. .
[3]
SoffiettiR, AbaciogluU, BaumertB, et al. Diagnosis and treatment of brain metastases from solid tumors: guidelines from the European Association of Neuro-Oncology(EANO)[J]. Neuro Oncol, 2017，19(2): 162-174. .
[4]
PatchellRA, TibbsPA, WalshJW, et al. A randomized trial of surgery in the treatment of single metastases to the brain[J]. N Engl J Med, 1990，322(8): 494-500. .
[5]
VechtCJ, Haaxma-ReicheH, NoordijkEM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery[J]. Ann Neurol, 1993，33(6): 583-590. .
[6]
PatchellRA, TibbsPA, RegineWF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial[J]. JAMA, 1998，280(17): 1485-1489.
[7]
McphersonCM, SukiD, Feiz-ErfanI, et al. Adjuvant whole-brain radiation therapy after surgical resection of single brain metastases[J]. Neuro Oncol, 2010，12(7): 711-719. .
[8]
BrownPD, BallmanKV, CerhanJH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC.3): a multicentre, randomised, controlled, phase 3 trial[J]. Lancet Oncol, 2017，18(8): 1049-1060. .
[9]
AndrewsDW, ScottCB, SperdutoPW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial[J]. Lancet, 2004，363(9422): 1665-1672. .
[10]
AoyamaH, ShiratoH, TagoM, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial[J]. JAMA, 2006，295(21): 2483-2491. .
[11]
KocherM, SoffiettiR, AbaciogluU, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952－26001 study[J]. J Clin Oncol, 2011，29(2): 134-141. .
[12]
BrownP, AsherA, BallmanK, et al. A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases[J]. Neuro Oncol, 2015，17(Suppl 5): v45-v46. .
[13]
SahgalA, AoyamaH, KocherM, et al. Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis[J]. Int J Radiat Oncol Biol Phys, 2015，91(4): 710-717. .
[14]
JairamV, ChiangVL, YuJB, et al. Role of stereotactic radiosurgery in patients with more than four brain metastases[J]. CNS Oncol, 2013，2(2): 181-193. .
[15]
KurtzJM, GelberR, BradyLW, et al. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group[J]. Int J Radiat Oncol Biol Phys, 1981，7(7): 891-895.
[16]
MurrayKJ, ScottC, GreenbergHM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104[J]. Int J Radiat Oncol Biol Phys, 1997，39(3): 571-574.
[17]
RadesD, SchildSE, LohynskaR, et al. Two radiation regimens and prognostic factors for brain metastases in nonsmall cell lung cancer patients[J]. Cancer, 2007，110(5): 1077-1082. .
[18]
MulvennaP, NankivellM, BartonR, et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial[J]. Lancet, 2016，388(10055): 2004-2014. .
[19]
BrownPD, PughS, LaackNN, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial[J]. Neuro Oncol, 2013，15(10): 1429-1437. .
[20]
GibsonE, MonjeM. Effect of cancer therapy on neural stem cells: implications for cognitive function[J]. Curr Opin Oncol, 2012，24(6): 672-678. .
[21]
GondiV, PughSL, TomeWA, et al. Preservation of memory with conformal avoidance of the hippocampal neural stem-cell compartment during whole-brain radiotherapy for brain metastases (RTOG 0933): a phase II multi-institutional trial[J]. J Clin Oncol, 2014，32(34): 3810-3816. .
[22]
FortinD. The blood-brain barrier: its influence in the treatment of brain tumors metastases[J]. Curr Cancer Drug Targets, 2012，12(3): 247-259.
[23]
MehtaMP. Brain metastases: the changing landscape[J]. Oncology (Williston Park), 2015，29(4): 257-260.
[24]
KimJE, LeeDH, ChoiY, et al. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis[J]. Lung Cancer, 2009，65(3): 351-354. .
[25]
SoriaJC, FelipE, CoboM, et al. Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial[J]. Lancet Oncol, 2015，16(8): 897-907. .
[26]
SchulerM, WuYL, HirshV, et al. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases[J]. J Thorac Oncol, 2016，11(3): 380-390. .
[27]
SoriaJC, OheY, VansteenkisteJ, et al. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer[J]. N Engl J Med, 2018，378(2): 113-125. .
[28]
YangZ, GuoQ, WangY, et al. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases[J]. Sci Transl Med, 2016，8(368): 368ra172. .
[29]
JiangT, MinW, LiY, et al. Radiotherapy plus EGFR TKIs in non-small cell lung cancer patients with brain metastases: an update meta-analysis[J]. Cancer Med, 2016，5(6): 1055-1065. .
[30]
EconomopoulouP, MountziosG. Non-small cell lung cancer (NSCLC) and central nervous system (CNS) metastases: role of tyrosine kinase inhibitors (TKIs) and evidence in favor or against their use with concurrent cranial radiotherapy[J]. Transl Lung Cancer Res, 2016，5(6): 588-598. .
[31]
GadgeelSM, ShawAT, GovindanR, et al. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer[J]. J Clin Oncol, 2016，34(34): 4079-4085. .
[32]
CrinòL, AhnMJ, De MarinisF, et al. Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND－2[J]. J Clin Oncol, 2016，34(24): 2866-2873. .
[33]
ShawAT, FelipE, BauerTM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial[J]. Lancet Oncol, 2017，18(12): 1590-1599. .
[34]
BerghoffAS, PreusserM. The inflammatory microenviron-ment in brain metastases: potential treatment target[J]. Chin Clin Oncol, 2015，4(2): 21. .
[35]
GoldbergSB, GettingerSN, MahajanA, et al. Pembro-lizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial[J]. Lancet Oncol, 2016，17(7): 976-983. .
[36]
TawbiHA, ForsythPA, AlgaziA, et al. Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain[J]. N Engl J Med, 2018，379(8): 722-730. .
[37]
LongG V, AtkinsonV, LoS, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study[J]. Lancet Oncol, 2018，19(5): 672-681. .
[38]
FormentiSC, DemariaS. Systemic effects of local radiotherapy[J]. Lancet Oncol, 2009，10(7): 718-726. .
[39]
Chicas-SettR, Morales-OrueI, Rodriguez-AbreuD, et al. Combining radiotherapy and ipilimumab induces clinically relevant radiation-induced abscopal effects in metastatic melanoma patients: A systematic review[J]. Clin Transl Radiat Oncol, 2018，9: 5-11. .
[40]
AhmedKA, KimS, ArringtonJ, et al. Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases[J]. J Neurooncol, 2017，133(2): 331-338. .
